Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RIG-C · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RIG-C | EXPERIMENTAL | Single 20 IU/kg dose of RIG-C by intramuscular injection |
| Name | Type | Description |
|---|---|---|
| RIG-C | BIOLOGICAL | - |
Inclusion Criteria: * In good health in the judgment of the Investigator as determined by medical history, physical examination, and screening laboratory assessments. * Female of childbearing potential must have a negative result on the screening serum pregnancy test and must agree to practice cont...
RIG-C is an investigational monoclonal antibody being developed for rabies. It is intended to provide rabies virus antibodies, and it is currently in Phase 1 clinical development. The drug is not yet approved and remains under study for this infectious disease indication.
RIG-C is being developed by Grifols, S.A., a biopharmaceutical company traded under the ticker GRFS. The company is conducting clinical research on this investigational monoclonal antibody for rabies.
RIG-C is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under study for rabies.
RIG-C has one completed clinical trial, NCT02139657, an open-label, single-arm study evaluating the safety and rabies virus antibody titers of intramuscularly administered rabies immune globulin. The trial enrolled 12 healthy volunteers in the United States.
RIG-C is being studied as a rabies immune globulin product. The completed clinical trial NCT02139657 evaluated the safety and rabies virus antibody titers of intramuscularly administered rabies immune globulin, which is the investigational product being developed by Grifols.